Prenatal diagnosis of fetal growth restriction with polyhydramnios, etiology and impact on postnatal outcome

Adeline Walter1, Elina Calite2, Christoph Berg2,3

  • 1Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. adeline.walter@ukbonn.de.

Scientific Reports
|January 11, 2022
PubMed

Insights

Fetal growth restriction (FGR) with polyhydramnios has high mortality. Five etiologic groups exist, with varying outcomes. Long-term follow-up is crucial, even for seemingly unaffected fetuses.

Area of Science:

  • Perinatology
  • Fetal Medicine
  • Genetics

Background:

  • Fetal growth restriction (FGR) and polyhydramnios are complex conditions.
  • Their combined occurrence presents diagnostic and prognostic challenges.
  • Understanding etiologies is key to managing these pregnancies.

Purpose of the Study:

  • To investigate the spectrum of causes for FGR with polyhydramnios.
  • To analyze the intrauterine course and outcomes.
  • To identify potential prognostic markers.

Main Methods:

  • Retrospective review of 153 cases diagnosed with FGR and polyhydramnios via prenatal ultrasound.
  • Analysis of ultrasound findings, prenatal, and postnatal outcomes.
  • Categorization into five etiological groups.

Main Results:

  • Five etiological groups identified: chromosomal anomalies (41.8%), complex malformations (24.1%), isolated malformations (15.7%), musculoskeletal disorders (9.2%), and non-anomalous (9.2%).
  • Significant disparities in diagnosis, amniotic fluid index (AFI)/gestational age ratio, and Doppler findings across groups.
  • Overall mortality rate was 64.7%; 42.9% of non-anomalous fetuses experienced further complications.

Conclusions:

  • FGR combined with polyhydramnios is associated with high morbidity and mortality.
  • Distinct etiological groups show significant differences in outcomes.
  • Long-term follow-up is essential due to potential neurodevelopmental or growth delays, even in cases without apparent prenatal anomalies.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.0K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.7K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.1K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
52